Weekly Insulin Icodec Plus Semaglutide for Type 2 Diabetes Management

For individuals with Type 2 Diabetes, achieving optimal glycemic control is crucial to prevent long-term complications. Current treatment regimens often involve daily insulin injections and other glucose-lowering medications, which can be complex and impact patient adherence. While GLP-1 receptor agonists like Semaglutide have shown significant benefits, the specific knowledge gap this study addresses is the efficacy and safety of combining a novel once-weekly basal insulin, Insulin Icodec, with Semaglutide in patients requiring intensified treatment.